Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Shtivelman

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Breast Cancer Research and Treatment|December 2, 2010
Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2Sreenivasan Paruthiyil, Aleksandra Cvoro, Mary Tagliaferri, et al.
Plos One|February 10, 2012
Bezielle selectively targets mitochondria of cancer cells to inhibit glycolysis and OXPHOSVivian Chen, Richard E Staub, Sylvia Fong, et al.
Plos One|January 25, 2012
Identification and analysis of the active phytochemicals from the anti-cancer botanical extract BezielleVivian Chen, Richard E Staub, Scott Baggett, et al.
Cancer Biology & Therapy|February 29, 2008
Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cellsSylvia Fong, Mark Shoemaker, Jaclyn Cadaoas, et al.
Oncotarget|April 12, 2014
Molecular pathways and therapeutic targets in lung cancerEmma Shtivelman, Thomas Hensing, George R Simon, et al.
Plos One|October 1, 2009
Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stressFrank W King, Sylvia Fong, Chandi Griffin, et al.
International Journal of Cancer|April 22, 2011
Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic studyJelena Klawitter, Jost Klawitter, Jennifer Gurshtein, et al.
Oncotarget|April 19, 2014
Pathways and therapeutic targets in melanomaEmma Shtivelman, Michael Q A Davies, Patrick Hwu, et al.
International Journal of Cancer|December 23, 2009
Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acidRuth Chu, Xiaoyue Zhao, Chandi Griffin, et al.
Breast Cancer Research and Treatment|November 18, 2006
Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancerHope Rugo, Emma Shtivelman, Alejandra Perez, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Breast Cancer Research and Treatment|December 2, 2010
Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2Sreenivasan Paruthiyil, Aleksandra Cvoro, Mary Tagliaferri, et al.
Plos One|February 10, 2012
Bezielle selectively targets mitochondria of cancer cells to inhibit glycolysis and OXPHOSVivian Chen, Richard E Staub, Sylvia Fong, et al.
Plos One|January 25, 2012
Identification and analysis of the active phytochemicals from the anti-cancer botanical extract BezielleVivian Chen, Richard E Staub, Scott Baggett, et al.
Cancer Biology & Therapy|February 29, 2008
Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cellsSylvia Fong, Mark Shoemaker, Jaclyn Cadaoas, et al.
Oncotarget|April 12, 2014
Molecular pathways and therapeutic targets in lung cancerEmma Shtivelman, Thomas Hensing, George R Simon, et al.
Plos One|October 1, 2009
Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stressFrank W King, Sylvia Fong, Chandi Griffin, et al.
International Journal of Cancer|April 22, 2011
Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic studyJelena Klawitter, Jost Klawitter, Jennifer Gurshtein, et al.
Oncotarget|April 19, 2014
Pathways and therapeutic targets in melanomaEmma Shtivelman, Michael Q A Davies, Patrick Hwu, et al.
International Journal of Cancer|December 23, 2009
Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acidRuth Chu, Xiaoyue Zhao, Chandi Griffin, et al.
Breast Cancer Research and Treatment|November 18, 2006
Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancerHope Rugo, Emma Shtivelman, Alejandra Perez, et al.
Pageof 3